Related references
Note: Only part of the references are listed.Clinical Outcomes of Patients With Breast Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience
Jennifer Wheler et al.
CLINICAL BREAST CANCER (2010)
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
Craig P. Carden et al.
DRUG DISCOVERY TODAY (2010)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials
Nicolai Juul et al.
LANCET ONCOLOGY (2010)
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
B. K. Linderholm et al.
ANNALS OF ONCOLOGY (2009)
Survival of Patients in a Phase 1 Clinic The M. D. Anderson Cancer Center Experience
Jennifer Wheler et al.
CANCER (2009)
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Olga K. Mirzoeva et al.
CANCER RESEARCH (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival
David J. Gallagher et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials
Hendrik-Tobias Arkenau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy
Valentina Guarneri et al.
ONCOLOGIST (2009)
Platinum-based chemotherapy in triple-negative breast cancer
B. Sirohi et al.
ANNALS OF ONCOLOGY (2008)
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
H-T Arkenau et al.
BRITISH JOURNAL OF CANCER (2008)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial?
Hendrik-Tobias Arkenau et al.
EUROPEAN JOURNAL OF CANCER (2008)
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer
Angela Chetrit et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The impact of new chemotherapeutic and agents on survival in a population-based of women with metastatic breast cancer hormone cohort
Stephen K. Chia et al.
CANCER (2007)
Trends in breast cancer by race and ethnicity: Update 2006
C Smigal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2006)
Goals of treatment for patients with metastatic breast cancer
I Smith
SEMINARS IN ONCOLOGY (2006)
Risks and benefits of phase 1 oncology trials, 1991 through 2002
E Horstmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Molecular mechanisms of drug resistance
DB Longley et al.
JOURNAL OF PATHOLOGY (2005)
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials
TG Roberts et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
